CA2433720A1 - An improved process for preparing pure ondansetron hydrochloride dihydrate - Google Patents
An improved process for preparing pure ondansetron hydrochloride dihydrate Download PDFInfo
- Publication number
- CA2433720A1 CA2433720A1 CA002433720A CA2433720A CA2433720A1 CA 2433720 A1 CA2433720 A1 CA 2433720A1 CA 002433720 A CA002433720 A CA 002433720A CA 2433720 A CA2433720 A CA 2433720A CA 2433720 A1 CA2433720 A1 CA 2433720A1
- Authority
- CA
- Canada
- Prior art keywords
- process according
- solution
- ondansetron
- methyl
- carbazolone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26105201P | 2001-01-11 | 2001-01-11 | |
| US60/261,052 | 2001-01-11 | ||
| PCT/US2002/000853 WO2002055492A2 (en) | 2001-01-11 | 2002-01-11 | An improved process for preparing pure ondansetron hydrochloride dihydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2433720A1 true CA2433720A1 (en) | 2002-07-18 |
Family
ID=22991757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002433720A Abandoned CA2433720A1 (en) | 2001-01-11 | 2002-01-11 | An improved process for preparing pure ondansetron hydrochloride dihydrate |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1355881A4 (ja) |
| JP (1) | JP2004526692A (ja) |
| KR (3) | KR20060113792A (ja) |
| CN (2) | CN101045704A (ja) |
| AU (1) | AU2002236753B2 (ja) |
| CA (1) | CA2433720A1 (ja) |
| CZ (1) | CZ20032090A3 (ja) |
| DE (1) | DE02703115T1 (ja) |
| ES (1) | ES2219201T1 (ja) |
| HR (1) | HRP20030631A2 (ja) |
| HU (1) | HUP0400767A2 (ja) |
| IL (1) | IL156835A0 (ja) |
| IS (1) | IS6869A (ja) |
| MX (1) | MXPA03006215A (ja) |
| NO (1) | NO20033147L (ja) |
| PL (1) | PL368837A1 (ja) |
| SK (1) | SK9892003A3 (ja) |
| TR (1) | TR200401460T3 (ja) |
| WO (1) | WO2002055492A2 (ja) |
| YU (1) | YU56103A (ja) |
| ZA (1) | ZA200305338B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098345B2 (en) | 2002-04-29 | 2006-08-29 | TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one |
| HU225885B1 (en) * | 2002-10-17 | 2007-11-28 | Richter Gedeon Nyrt | Process for producing ondansetron hydrochlorid dihydrate of high purity |
| FI6164U1 (fi) * | 2003-01-09 | 2004-03-15 | Synthon Bv | Ondansetronmuotoja |
| GB2398071B (en) * | 2003-01-24 | 2006-06-07 | Synthon Bv | Process for making ondansetron and intermediate thereof |
| US7696356B2 (en) | 2004-08-17 | 2010-04-13 | Taro Pharmaceutical Industries Limited | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom |
| US7547791B2 (en) * | 2004-10-26 | 2009-06-16 | Ipca Laboratories Ltd. | One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| GB8630071D0 (en) * | 1986-12-17 | 1987-01-28 | Glaxo Group Ltd | Medicaments |
| CN1498216A (zh) * | 2000-10-30 | 2004-05-19 | ������ҩ��ҵ����˾ | 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法 |
-
2002
- 2002-01-11 KR KR1020067020069A patent/KR20060113792A/ko not_active Application Discontinuation
- 2002-01-11 DE DE02703115T patent/DE02703115T1/de active Pending
- 2002-01-11 KR KR10-2003-7009221A patent/KR20030068583A/ko active IP Right Grant
- 2002-01-11 ES ES02703115T patent/ES2219201T1/es active Pending
- 2002-01-11 AU AU2002236753A patent/AU2002236753B2/en not_active Expired - Fee Related
- 2002-01-11 MX MXPA03006215A patent/MXPA03006215A/es unknown
- 2002-01-11 CZ CZ20032090A patent/CZ20032090A3/cs unknown
- 2002-01-11 CN CNA2006101667179A patent/CN101045704A/zh active Pending
- 2002-01-11 ZA ZA200305338A patent/ZA200305338B/xx unknown
- 2002-01-11 PL PL02368837A patent/PL368837A1/xx not_active Application Discontinuation
- 2002-01-11 IL IL15683502A patent/IL156835A0/xx unknown
- 2002-01-11 YU YU56103A patent/YU56103A/sh unknown
- 2002-01-11 JP JP2002556165A patent/JP2004526692A/ja active Pending
- 2002-01-11 HU HU0400767A patent/HUP0400767A2/hu unknown
- 2002-01-11 KR KR1020077010146A patent/KR20070054749A/ko not_active Application Discontinuation
- 2002-01-11 TR TR2004/01460T patent/TR200401460T3/xx unknown
- 2002-01-11 CN CNA028062019A patent/CN1496350A/zh active Pending
- 2002-01-11 SK SK989-2003A patent/SK9892003A3/sk not_active Application Discontinuation
- 2002-01-11 CA CA002433720A patent/CA2433720A1/en not_active Abandoned
- 2002-01-11 WO PCT/US2002/000853 patent/WO2002055492A2/en active Application Filing
- 2002-01-11 EP EP02703115A patent/EP1355881A4/en not_active Withdrawn
-
2003
- 2003-07-08 IS IS6869A patent/IS6869A/is unknown
- 2003-07-09 NO NO20033147A patent/NO20033147L/no not_active Application Discontinuation
- 2003-08-06 HR HR20030631A patent/HRP20030631A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004526692A (ja) | 2004-09-02 |
| TR200401460T3 (ja) | 2004-08-23 |
| SK9892003A3 (en) | 2004-05-04 |
| CZ20032090A3 (cs) | 2004-08-18 |
| EP1355881A2 (en) | 2003-10-29 |
| MXPA03006215A (es) | 2005-02-17 |
| KR20070054749A (ko) | 2007-05-29 |
| IS6869A (is) | 2003-07-08 |
| DE02703115T1 (de) | 2004-10-21 |
| KR20060113792A (ko) | 2006-11-02 |
| CN101045704A (zh) | 2007-10-03 |
| YU56103A (sh) | 2006-05-25 |
| KR20030068583A (ko) | 2003-08-21 |
| HRP20030631A2 (en) | 2005-06-30 |
| NO20033147D0 (no) | 2003-07-09 |
| ZA200305338B (en) | 2004-07-12 |
| PL368837A1 (en) | 2005-04-04 |
| WO2002055492A2 (en) | 2002-07-18 |
| HUP0400767A2 (hu) | 2004-07-28 |
| WO2002055492A3 (en) | 2003-02-13 |
| IL156835A0 (en) | 2004-02-08 |
| ES2219201T1 (es) | 2004-12-01 |
| AU2002236753B2 (en) | 2007-06-28 |
| NO20033147L (no) | 2003-09-02 |
| EP1355881A4 (en) | 2004-03-31 |
| CN1496350A (zh) | 2004-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105503834B (zh) | 一种伏立康唑中间体的合成方法 | |
| US7777037B2 (en) | Ziprasidone process | |
| CA2942301A1 (en) | Clomiphene synthesis using a single solvent | |
| JP2004530638A (ja) | 結晶性ベンラファクシン塩基、及び新規なベンラファクシン塩酸塩多型形状、ならびにその調製方法 | |
| EP3015453B1 (en) | Process for the preparation of Clomiphene | |
| HU228204B1 (en) | New process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and use thereof for the synthesis of tianeptine | |
| JP2008511684A (ja) | アナストロゾール中間体についての精製方法 | |
| AU2002236753B2 (en) | An improved process for preparing pure ondansetron hydrochloride dihydrate | |
| KR20080000621A (ko) | 항암 약물의 제조 방법 | |
| AU2002236753A1 (en) | An improved process for preparing pure ondansetron hydrochloride dihydrate | |
| US5877351A (en) | Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts | |
| US20100063299A1 (en) | Process for Preparing Irbesartan | |
| TWI291956B (en) | Improved process | |
| US20020115707A1 (en) | Process for preparing pure ondansetron hydrochloride dihydrate | |
| CN101883766A (zh) | 制备佐米曲普坦、其盐和溶剂化物的方法 | |
| US20120253051A1 (en) | Process for the preparation of ropinirole and salts thereof | |
| EP3015454A1 (en) | Stable solid form of trans-Clomiphene citrate | |
| EP2657232A2 (en) | Process for the purification of a benzenesulphonamide compound | |
| JP6275596B2 (ja) | テルミサルタンのアンモニウム塩の製造方法 | |
| EP1720867A2 (en) | Process for the preparation of ziprasidone | |
| EP2072510A1 (en) | Crystalline form of azelastine | |
| CA2688463A1 (en) | Process for the preparation of rizatriptan | |
| KR100342919B1 (ko) | 트랜스체 염산 트라마돌의 분리 제조방법 | |
| EP3074374A2 (en) | Fingolimod hydrochloride process | |
| WO1991017973A1 (en) | 5H-DIBENZO(a,d)CYCLOHEPTENES AS MUSCARINIC RECEPTOR ANTAGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |